Search - tctmd.com

Displaying 361 - 380 of 621

Sort: Relevancy | Date

News Conference News SCCT 2019

Time to Ease Up on Prior Authorization for PCSK9 Inhibitors?

Yael L. Maxwell

July 15, 2019

News Conference News SCCT 2019

Imaging, Genes, Wearables: Some Predictions for the Future of Preventive Cardiology

Yael L. Maxwell

July 15, 2019

News Daily News

Most Supplements and Diets Don’t Lower CVD or Mortality Risks

Michael O'Riordan

July 09, 2019

News Daily News

Age Without Atherosclerosis: Tests May Help Elderly Skip Statins

Yael L. Maxwell

July 04, 2019

News Daily News

High Levels of Lp(a) Linked to Increased Ischemic Stroke Risk

Michael O'Riordan

July 01, 2019

News Daily News

Exposure to Air Pollution in China Tied to Increase in Coronary Calcium

Todd Neale

June 28, 2019

News Daily News

To Battle CVD in China, the ‘Healthcare Pyramid’ Must Be Flipped

L.A. McKeown

June 25, 2019

News Conference News EAS 2019

Should Lp(a) Be Measured and Treated? Two Experts Hash Out Its Current Role

Michael O'Riordan

June 07, 2019

News Conference News EAS 2019

Absence of FH Diagnosis Linked to Increased Risk of Premature Mortality

Michael O'Riordan

June 05, 2019

News Conference News SCAI 2019

LDL Apheresis Potentially a ‘Head Start’ to Conventional Lipid-Lowering Methods Post-PCI in ACS: PREMIER

Yael L. Maxwell

June 03, 2019

News Conference News EAS 2019

FH Patients Derive Biggest Absolute Benefit From Statin Therapy: 4S Analysis

Michael O'Riordan

June 03, 2019

News Conference News EAS 2019

Bempedoic Acid/Ezetimibe Combo Lowers LDL Cholesterol in High-Risk Patients

Michael O'Riordan

May 30, 2019

News Conference News EAS 2019

CHD Mortality Significantly Elevated in Patients With Severe FH

Michael O'Riordan

May 29, 2019

News Conference News EAS 2019

Clear CVD Risk Reduction With PCSK9 Inhibitors, but No Mortality Effect: Meta-analysis

Michael O'Riordan

May 28, 2019

News Daily News

Residual Inflammatory Risk and PCI: Worthy Biomarker or Merely Something Else to Measure?

Yael L. Maxwell

May 15, 2019

News Daily News

AHA Advisory Emphasizes Need for Food-System Innovation, and Proof That It Works

Yael L. Maxwell

May 02, 2019

News Daily News

PCSK9 Inhibitor Alirocumab Receives Expanded Indication for CV Event Reduction

Michael O'Riordan

April 29, 2019

News Daily News

Lengthy Antibiotic Use Later in Life Tied to Higher CV Risk for Women

Caitlin E. Cox

April 25, 2019

News Daily News

Will Less Aggressive Lp(a) Targets Do the Trick? Time and Clinical Trials Will Tell

Yael L. Maxwell

April 24, 2019

News Daily News

No Need for Niacin? Meta-analysis Argues the End Is Nigh

Yael L. Maxwell

April 22, 2019

Advertisement

Time to Ease Up on Prior Authorization for PCSK9 Inhibitors?

Imaging, Genes, Wearables: Some Predictions for the Future of Preventive Cardiology

Most Supplements and Diets Don’t Lower CVD or Mortality Risks

Age Without Atherosclerosis: Tests May Help Elderly Skip Statins

High Levels of Lp(a) Linked to Increased Ischemic Stroke Risk

Exposure to Air Pollution in China Tied to Increase in Coronary Calcium

To Battle CVD in China, the ‘Healthcare Pyramid’ Must Be Flipped

Should Lp(a) Be Measured and Treated? Two Experts Hash Out Its Current Role

Absence of FH Diagnosis Linked to Increased Risk of Premature Mortality

LDL Apheresis Potentially a ‘Head Start’ to Conventional Lipid-Lowering Methods Post-PCI in ACS: PREMIER

FH Patients Derive Biggest Absolute Benefit From Statin Therapy: 4S Analysis

Bempedoic Acid/Ezetimibe Combo Lowers LDL Cholesterol in High-Risk Patients

CHD Mortality Significantly Elevated in Patients With Severe FH

Clear CVD Risk Reduction With PCSK9 Inhibitors, but No Mortality Effect: Meta-analysis

Residual Inflammatory Risk and PCI: Worthy Biomarker or Merely Something Else to Measure?

AHA Advisory Emphasizes Need for Food-System Innovation, and Proof That It Works

PCSK9 Inhibitor Alirocumab Receives Expanded Indication for CV Event Reduction

Lengthy Antibiotic Use Later in Life Tied to Higher CV Risk for Women

Will Less Aggressive Lp(a) Targets Do the Trick? Time and Clinical Trials Will Tell

No Need for Niacin? Meta-analysis Argues the End Is Nigh

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content